Core--Protocol Management and Coordination of Multi-center Trials
核心--多中心试验的方案管理和协调
基本信息
- 批准号:7478453
- 负责人:
- 金额:$ 52.64万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-08-01 至 2011-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse eventCategoriesClinicalClinical DataCollaborationsDataData AnalysesData CollectionData Coordinating CenterDatabasesDiseaseEligibility DeterminationFeedbackGrantInstitutionOutcomePatientsProcessProtocols documentationReportingResearchResearch Ethics CommitteesResourcesRoleSamplingServicesSpecimenTimeTransplant RecipientsTransplantationbasefollow-upimmune functionsample collectionstatistics
项目摘要
The services provided by the Protocol Management and Coordination of Multi-Center Trials Core, are
multifaceted. First, the Core will provide the mechanism for the regulatory management of protocols including the process for IRB approval. Second, it will determine patient
eligibility and registration to protocols. Third, it will facilitate protocol implementation including the
coordination of protocol-specific patient workups, research specimen collections, and adverse event
reporting on a real time basis. Fourth, it will coordinate clinical data collection that is protocol-specific.
Finally, it will serve as the data coordination center for the multi-center trials proposed. Multi-center
studies are critical for the studies proposed in these projects because the planned transplantation
protocols address relatively uncommon diseases. Accrual of patients in these disease categories to any
one center is likely to be limited, and more rapid accrual can be achieved through multi-center
collaboration. Such collaborations require coordination of data collection, feedback to participating
institutions, and multi-center assurances of IRB requirements. This Core will provide resources to obtain
outcome data for analysis of these trials. The role of this Core is to coordinate and gather data from the
collaborative network outside of Seattle, and to integrate data from the central patient database
maintained by Clinical Statistics with data collected solely for the multi-center studies. The
Long-Term Follow-Up (LTFU) department provides follow-up on all Seattle patients transplanted under
the auspices of this grant, and, where appropriate, these data are then integrated
into the multi-center database. This Core is also responsible for coordinating the acquisition of research
samples for the Immune Function Studies Core.
多中心试验方案管理和协调中心提供的服务包括:
多方面的首先,核心将提供方案监管管理机制,包括IRB批准流程。其次,它将决定病人
方案的资格和登记。第三,它将促进协议的实施,包括
协调方案特定的患者检查、研究标本采集和不良事件
以真实的时间为基础进行报告。第四,它将协调方案特定的临床数据收集。
最后,它将作为多中心试验的数据协调中心。多中心
这些研究对这些项目中提出的研究至关重要,因为计划的移植
协议针对相对罕见的疾病。这些疾病类别中的患者应计任何
一个中心可能是有限的,通过多中心可以实现更快的累积
协作这种合作需要协调数据收集,反馈参与
机构,以及IRB要求的多中心保证。该核心将提供资源,
分析这些试验的结果数据。该核心的作用是协调和收集来自
西雅图以外的协作网络,并整合来自中央患者数据库的数据
由临床统计部维护,仅为多中心研究收集数据。的
长期随访(LTFU)部门为所有西雅图移植患者提供随访,
该补助金的赞助,并在适当的情况下,这些数据,然后整合
多中心数据库。该核心还负责协调研究的获取
免疫功能研究核心的样本。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
BRENDA MARIE SANDMAIER其他文献
BRENDA MARIE SANDMAIER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('BRENDA MARIE SANDMAIER', 18)}}的其他基金
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells
Alpha 发射体标记的抗 T 细胞抗体:针对潜伏的 HIV 感染细胞
- 批准号:
9301083 - 财政年份:2016
- 资助金额:
$ 52.64万 - 项目类别:
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells
Alpha 发射体标记的抗 T 细胞抗体:针对潜伏的 HIV 感染细胞
- 批准号:
9327864 - 财政年份:2016
- 资助金额:
$ 52.64万 - 项目类别:
Alpha Emitter Labeled Anti-T Cell Antibody: Targeting Latent HIV Infected Cells
Alpha 发射体标记的抗 T 细胞抗体:针对潜伏的 HIV 感染细胞
- 批准号:
8842434 - 财政年份:2014
- 资助金额:
$ 52.64万 - 项目类别:
Alpha Radioimmunotherapy for Lymphoma Treatment
淋巴瘤治疗的阿尔法放射免疫疗法
- 批准号:
8782611 - 财政年份:2013
- 资助金额:
$ 52.64万 - 项目类别:
Alpha Radioimmunotherapy for Lymphoma Treatment
淋巴瘤治疗的阿尔法放射免疫疗法
- 批准号:
8601179 - 财政年份:2013
- 资助金额:
$ 52.64万 - 项目类别:
Allogeneic HCT for Hematologic Malignancies: Immune Manipulations
同种异体 HCT 治疗血液系统恶性肿瘤:免疫操作
- 批准号:
8240005 - 财政年份:2011
- 资助金额:
$ 52.64万 - 项目类别:
Allogeneic HCT for Hematologic Malignancies: Immune Manipulations
同种异体 HCT 治疗血液系统恶性肿瘤:免疫操作
- 批准号:
7585357 - 财政年份:2009
- 资助金额:
$ 52.64万 - 项目类别:
Nonmyeloablative Allografts in DLA-haploidentical Dogs: Engraftment and GVHD
DLA 单倍体狗的非清髓性同种异体移植:移植和 GVHD
- 批准号:
7478449 - 财政年份:2007
- 资助金额:
$ 52.64万 - 项目类别:
Core--Protocol Management and Coordination of Multi-center Trials
核心--多中心试验的方案管理和协调
- 批准号:
7304871 - 财政年份:2006
- 资助金额:
$ 52.64万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 52.64万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 52.64万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 52.64万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 52.64万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 52.64万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 52.64万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 52.64万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 52.64万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 52.64万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 52.64万 - 项目类别: